H
HBM Alpha Therapeutics develops novel antibody therapeutics targeting endocrine disorders with significant unmet medical needs. The company's lead programs focus on precision treatments for congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). These therapies aim to offer improved management by targeting specific pathways related to the hypothalamus-pituitary-adrenal axis.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- HBM Alpha Therapeutics develops novel antibody therapeutics targeting endocrine disorders with significant unmet medical needs. The company's lead programs focus on precision treatments for congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). These therapies aim to offer improved management by targeting specific pathways related to the hypothalamus-pituitary-adrenal axis.